PanOptica
Participant:
![Paul Chaney](https://ois.net/wp-content/uploads/2015/12/Paul-Chaney-WEB.jpg)
Paul Chaney
Paul G. Chaney is Co-Founder, President & CEO of PanOptica Inc., a biopharma company developing PAN-90806, a novel topical anti-VEGF treatment for neovascular eye diseases.
Paul G. Chaney is Co-Founder, President & CEO of PanOptica Inc., a biopharma company developing PAN-90806, a novel topical anti-VEGF treatment for neovascular eye diseases.